EuroAspire VI

Objectives

The objectives of EUROASPIRE VI survey of CVD prevention, diabetes and chronic kidney disease are:

1. To determine in patients with established CHD (CHD = acute myocardial infarction (AMI) and acute ischaemia (unstable angina) and patients following revascularisation by a percutaneous coronary intervention (PCI) or coronary artery by-pass graft surgery (CABG)) and in patients at high risk of developing CVD risk, whether the 2021 European guidelines on CVD prevention are being followed.
2. To compare diagnostic and therapeutic strategies in CHD and high-risk patients for hypertension to determine whether the 2018 European guidelines on hypertension are being followed.
3. To compare diagnostic and therapeutic strategies in CHD and high-risk patients for glucose metabolism (impaired fasting glycaemia, impaired glucose tolerance and diabetes) to determine whether the 2019 European guidelines on diabetes, prediabetes and CVD are being followed.
4. To compare diagnostic and therapeutic strategies in CHD and high-risk patients, including those with familial hypercholesterolaemia, for their lipid (total cholesterol, HDL-cholesterol, triglycerides and Lp(a)) management to determine whether the 2019 lipid guidelines are being followed.
5. To compare diagnostic and therapeutic strategies in CHD and high-risk patients for chronic kidney disease (either albuminuria and/or reduced kidney function defined as an eGFR <60 ml/min/1.73 m2) to determine whether the CKD guidelines (ADA/EASD, KDIGO) are being followed.
6. To determine whether organ-protective medications, that protect the heart and the kidneys as recommended in the guidelines, are prescribed (and up-titrated to the correct doses as appropriate) in every day clinical practice.
7. To determine whether the preventive strategies in patients with established CHD in EUROASPIRE VI has improved by comparison with those hospital centres which took part in previous EUROASPIRE surveys and whether the practice of preventive cardiology in patients in primary care at high CVD risk in EUROASPIRE VI has improved by comparison with those centres which took part in EUROASPIRE III, IV and V.
8. To follow-up all coronary patients from EUROASPIRE VI one and five years after the interview for hospitalisations, cardiovascular procedures, cardiovascular events and cardiovascular and all cause mortality to determine the impact of risk factors for CVD and their management and event-free survival.
9. To identify strategies for improving preventive care based on the EUROASPIRE survey results from hospital and general practice, and to make policy and practice recommendations to the European Association for Preventive Cardiology and future ESC Guidelines on CVD Prevention.